Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 1,760 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #1 Clear all

Conditions: Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer
Interventions: MCLA-158, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI, MCLA-158 + FOLFOX; Drug · Combination Product
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 31
States / cities: La Jolla, California • Los Angeles, California • San Diego, California + 25 more

Conditions: Dentin Sensitivity
Interventions: Placebo, 15% nano-HAP toothpaste, 5% KNO3 toothpaste; Other · Device
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 20 Years to 80 Years
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chronic Weight Management
Interventions: ASC36 tablets, for oral use, ASC36 placebo tablets; Drug
Lead sponsor: Ascletis Pharma (China) Co., Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Contraception
Interventions: NOMAC-E2 COC; Drug
Lead sponsor: Organon and Co; Industry
Eligibility: 14 Years to 35 Years · Female only
Enrollment: 3,055 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 103
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 79 more

Conditions: Healthy
Interventions: crizotinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Woburn, Massachusetts

Conditions: Polycystic Ovary Syndrome
Interventions: Yasmin; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 15 Years to 40 Years · Female only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Adenocarcinoma, Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions: Atezolizumab, Nab-paclitaxel; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Metformin, DA-1241; Drug
Lead sponsor: Dong-A ST Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions: UGN-103; Drug
Lead sponsor: UroGen Pharma Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 17
States / cities: Loma Linda, California • San Diego, California • Washington D.C., District of Columbia + 12 more

Conditions: Influenza
Interventions: GSK2340274A, GSK2340273A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 8 Years
Enrollment: 323 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 17
States / cities: Conway, Arkansas • Little Rock, Arkansas • Sacramento, California + 14 more

Conditions: Healthy
Interventions: tenofovir, emtricitabine and efavirenz fixed dose tablet, tenofovir, emtricitabine and efavirenz tablet added to solution; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Influenza
Interventions: Fluzone Quadrivalent vaccine, 2018-2019 formulation, Flublok Quadrivalent vaccine, 2018-2019 formulation, Fluzone High-Dose vaccine, 2018-2019 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 3
States / cities: Bardstown, Kentucky • Metairie, Louisiana • Salt Lake City, Utah

Conditions: COVID-19
Interventions: SARS-CoV-2 mRNA vaccine formulation 1, SARS-CoV-2 mRNA vaccine formulation 2, SARS-CoV-2 mRNA vaccine formulation 3, Placebo (0.9% normal saline); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 12
States / cities: Rolling Hills Estates, California • Hollywood, Florida • Miami, Florida + 9 more

Conditions: Healthy
Interventions: PF-05175157; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Human Immunodeficiency Virus Type 1
Interventions: TMC278 25 mg, TMC278 75 mg, TMC278 150 mg, Efavirenz, Non-nucleoside reverse transcriptase inhibitor (NRTIs); Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 9
States / cities: Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 6 more

Conditions: Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions: sargramostim, paclitaxel albumin-stabilized nanoparticle formulation, laboratory biomarker analysis, immunologic technique; Biological · Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chikungunya Virus
Interventions: CHIKV VLP, adjuvanted; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Diabetic Foot Ulcers
Interventions: Granexin gel, Vehicle gel; Drug · Other
Lead sponsor: Xequel Bio, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Los Angeles, California • Doral, Florida • Hialeah, Florida + 3 more

Conditions: Recurrent Bladder Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma
Interventions: Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Quality-of-Life Assessment; Other · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2016
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Vulvovaginal Candidiases, Vulvovaginal Candidiasis, Genital, Vulvovaginal Candidiasis (VVC)
Interventions: Boric acid, Placebo; Drug · Other
Lead sponsor: pH-D Feminine Health LLC; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 26
States / cities: Mobile, Alabama • Little Rock, Arkansas • Huntington Park, California + 20 more

Conditions: Healthy
Interventions: PF-07799933 tablets with PF-07799544 fasted, PF-07799933 film-coated tablets with PF-07799544 fasted, PF-07799933 film-coated tablets with PF-07799544 fed, PF-07799933 film-coated tablets fasted, PF-07799933 film-coated tablets following rabeprazole pretreatment fasted; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Staphylococcus Aureus Bacteremia
Interventions: 514G3 (2 mg/kg) plus standard IV antibiotic treatment, 514G3 (10 mg/kg) plus standard IV antibiotic treatment, 514G3 (40 mg/kg) plus standard IV antibiotic treatment, Placebo plus standard IV antibiotic treatment, 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II, Placebo plus standard IV antibiotic treatment: Phase II; Biological · Other
Lead sponsor: XBiotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Columbus, Georgia • Charlotte, North Carolina

Conditions: Norovirus
Interventions: Adjuvant/Excipients, placebo, Norwalk VLP Vaccine; Drug · Device · Biological
Lead sponsor: LigoCyte Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: Baltimore, Maryland • St Louis, Missouri • Rochester, New York + 1 more

Conditions: Influenza
Interventions: Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation, Influenza Virus Vaccine: Fluzone® Intradermal 2012-2013 Formulation, Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Boca Raton, Florida • South Miami, Florida • Council Bluffs, Iowa + 1 more

Search by objective public record fields.

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Trial of Nano-hydroxyapatite-Containing Toothpastes for Relief of Dentin Hypersensitivity

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC36 Tablets for Oral Use in Adult Participants With Obesity or Overweight

Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive

A Study To Investigate The Taste Of Crizotinib Liquid In Trained Healthy Adult Volunteers

Continuous Versus Cyclical OCP Use in PCOS

Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male Subjects

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age

The Bioequivalence of Atripla in an Oral Liquid Formulation Compared With the Tablet Formulation in Healthy Volunteers

Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older

A Healthy Volunteer Study To Assess Relative Bioavailability Of Powder-In-Capsule And A Tablet Formulation And The Effect Of Food On The Pharmacokinetics Of The Tablet Formulation

A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy

A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine

A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer

Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer

Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis

Relative Bioavailability and Impact of Rabeprazole for PF-07799933, Food-Effect for PF-07799933 and PF-07799544

Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.

Phase 1 Norwalk Vaccine Study

Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.